Medicus Pharma seeks FDA orphan drug status for novel microneedle skin cancer therapy
Medicus Pharma (NASDAQ:MDCX), a clinical-stage biopharmaceutical company, announced today that it has submitted an application for Orphan Drug Designation (ODD) to the U.S. Food and Drug Administration (FDA) for its flagship candidate, SkinJect (D-MNA).



_1382209_640x360_2496776259638-640x360.webp&w=3840&q=75)





_1382120_640x360_2496768579652-640x360.webp&w=3840&q=75)

